Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
One important approach to change the natural history of advanced breast cancer is that of
designing new combination chemotherapies in which the best drugs already available are used
together with new anticancer agents devoid of clinical cross-resistance. The possibility of
exploiting the combined use of cetuximab and trastuzumab represents an option of potential
great impact on the probability of response and long-term therapeutic results for patients
with advanced breast cancer and HER2 overexpression.Therefore, patients with tumors that
demonstrate EGFR expression and clear-cut erbB-2 overexpression (3+) or limited erbB-2
overexpression (+ or 2+) will be included in the study. Patients will be treated with
trastuzumab and cetuximab to study the pharmacokinetics and potential drug/drug interaction
of both antibodies as well as the safety and tolerability of this novel combination
treatment.